Revvity Exceeds Q1 Expectations and Announces Strategic Divestiture of China Immunodiagnostics Business
RVTY is trading near its 52-week low of $81.22 (4.9% above the low).
Summary
Revvity reported strong Q1 2026 financial results, exceeding expectations, and announced the strategic divestiture of its China Immunodiagnostics business for up to $200 million, updating full-year guidance accordingly.
Key Events · Earnings and Guidance · RVTY
-
Strong Q1 Financial Performance
Revvity reported Q1 2026 revenue of $711 million, a 7% year-over-year increase, with 3% organic growth (6% pro forma organic growth). Adjusted EPS from continuing operations reached $1.06, surpassing prior expectations.
-
Strategic Divestiture of China Immunodiagnostics Business
The company announced its intention to divest its Immunodiagnostics business in China (China IDX), which accounted for approximately 6% of its FY2025 revenue. A letter of intent has been signed for a sale of up to $200 million, with a potential consideration of $140 million reflected in pro forma statements, and is expected to close in 2027. This divestiture will result in a $55 million loss on probable disposition.
-
Updated Full-Year 2026 Guidance
Revvity updated its full-year 2026 guidance on a pro forma basis, forecasting total revenue of $2.81-$2.84 billion, pro forma organic revenue growth of 3%-4%, and pro forma adjusted EPS of $5.20-$5.30, reflecting the exclusion of the divested China IDX business.
Analysis · RVTY · Industrial Applications And Services
Revvity, Inc. reported strong first-quarter results, with revenue increasing 7% year-over-year to $711 million and adjusted EPS of $1.06, both exceeding expectations. Concurrently, the company announced a strategic decision to divest its Immunodiagnostics business in China (China IDX), which represented approximately 6% of its total fiscal year 2025 revenue. The sale is for up to $200 million, with a potential consideration of $140 million reflected in pro forma statements, and is expected to close in 2027. This divestiture, while resulting in a $55 million loss on probable disposition, is framed as a portfolio optimization. The company has updated its full-year 2026 guidance on a pro forma basis, reflecting the exclusion of the divested business. This filing provides comprehensive details following earlier news reports of strong Q1 performance, and the strategic divestiture marks a significant shift in the company's operational focus, potentially streamlining its business and improving long-term profitability, especially as the stock trades near its 52-week low.
At the time of this filing, RVTY was trading at $85.18 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $9.7B. The 52-week trading range was $81.22 to $118.30. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.